Literature DB >> 20144674

Identification of a novel chemical potentiator and inhibitors of UCH-L1 by in silico drug screening.

Takeshi Mitsui1, Kazunori Hirayama, Shunsuke Aoki, Kaori Nishikawa, Kenko Uchida, Takashi Matsumoto, Tomohiro Kabuta, Keiji Wada.   

Abstract

Ubiquitin-C-terminal hydrolase L1 (UCH-L1) is a de-ubiquitinating enzyme expressed in the brain and reproductive tissues as well as certain cancers. The hydrolase activity of UCH-L1 has been implicated in Alzheimer's disease and cancer invasion; therefore, it may represent a therapeutic target for these diseases. The present study was undertaken to identify novel chemical modulators for the hydrolase activity of UCH-L1. To identify chemicals that bind to the active site of UCH-L1, we carried out in silico structure-based drug screening using human UCH-L1 crystal structure data (PDB ID: 2ETL) and virtual compound libraries containing 26,891 and 304,205 compounds. Among the compounds with the highest binding scores, we identified one that potentiates the hydrolase activity of UCH-L1, and six that inhibit the activity in enzymatic assays. These compounds may be useful for research on UCH-L1 function, and could lead to candidate therapeutics for UCH-L1-associated diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20144674     DOI: 10.1016/j.neuint.2010.01.016

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  9 in total

1.  The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK).

Authors:  Christopher W Davies; Joseph Chaney; Gregory Korbel; Dagmar Ringe; Gregory A Petsko; Hidde Ploegh; Chittaranjan Das
Journal:  Bioorg Med Chem Lett       Date:  2012-05-04       Impact factor: 2.823

Review 2.  Balancing act: deubiquitinating enzymes in the nervous system.

Authors:  Sokol V Todi; Henry L Paulson
Journal:  Trends Neurosci       Date:  2011-06-24       Impact factor: 13.837

3.  Isopeptidases in anticancer therapy: looking for inhibitors.

Authors:  Andrea Sgorbissa; Harish Potu; Claudio Brancolini
Journal:  Am J Transl Res       Date:  2010-05-10       Impact factor: 4.060

Review 4.  Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors.

Authors:  Mark Kemp
Journal:  Prog Med Chem       Date:  2016-01-12

5.  An Effective Method to Identify Shared Pathways and Common Factors among Neurodegenerative Diseases.

Authors:  Ping Li; Yaling Nie; Jingkai Yu
Journal:  PLoS One       Date:  2015-11-17       Impact factor: 3.240

Review 6.  Deubiquitylating enzymes and DNA damage response pathways.

Authors:  Xavier Jacq; Mark Kemp; Niall M B Martin; Stephen P Jackson
Journal:  Cell Biochem Biophys       Date:  2013-09       Impact factor: 2.194

7.  Inhibition of UCH-L1 Deubiquitinating Activity with Two Forms of LDN-57444 Has Anti-Invasive Effects in Metastatic Carcinoma Cells.

Authors:  Eiji Kobayashi; Duhyeong Hwang; Anjali Bheda-Malge; Christopher B Whitehurst; Alexander V Kabanov; Satoru Kondo; Mitsuharu Aga; Tomokazu Yoshizaki; Joseph S Pagano; Marina Sokolsky; Julia Shakelford
Journal:  Int J Mol Sci       Date:  2019-07-31       Impact factor: 5.923

8.  Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression.

Authors:  Suet-Ying Kwan; Chi-Lam Au-Yeung; Tsz-Lun Yeung; Angela Rynne-Vidal; Kwong-Kwok Wong; John I Risinger; Hui-Kuan Lin; Rosemarie E Schmandt; Melinda S Yates; Samuel C Mok; Karen H Lu
Journal:  Cancers (Basel)       Date:  2020-01-02       Impact factor: 6.639

Review 9.  Sphingolipids as a Novel Therapeutic Target in Radiation-Induced Lung Injury.

Authors:  Jeffrey R Jacobson
Journal:  Cell Biochem Biophys       Date:  2021-08-09       Impact factor: 2.194

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.